The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases
Abstract
PPARs (peroxisome-proliferator-activated receptors) are ligand-activated transcriptional factor receptors belonging to the so-called nuclear receptor family. The three isoforms of PPAR (α, β/δ and γ) are involved in regulation of lipid or glucose metabolism. Beyond metabolic effects, PPARα and PPARγ activation also induces anti-inflammatory and antioxidant effects in different organs. These pleiotropic effects explain why PPARα or PPARγ activation has been tested as a neuroprotective agent in cerebral ischaemia. Fibrates and other non-fibrate PPARα activators as well as thiazolidinediones and other non-thiazolidinedione PPARγ agonists have been demonstrated to induce both preventive and acute neuroprotection. This neuroprotective effect involves both cerebral and vascular mechanisms. PPAR activation induces a decrease in neuronal death by prevention of oxidative or inflammatory mechanisms implicated in cerebral injury. PPARα activation induces also a vascular protection as demonstrated by prevention of post-ischaemic endothelial dysfunction. These vascular effects result from a decrease in oxidative stress and prevention of adhesion proteins, such as vascular cell adhesion molecule 1 or intercellular cell-adhesion molecule 1. Moreover, PPAR activation might be able to induce neurorepair and endothelium regeneration. Beyond neuroprotection in cerebral ischaemia, PPARs are also pertinent pharmacological targets to induce neuroprotection in chronic neurodegenerative diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oxidative stress in neurodegeneration: Cause or consequence?
Andersen, J. K. (2004) · Nature Medicine · doi:10.1038/nrn1434 · Cited by 1,869
PPARs: therapeutic targets for metabolic disease
Berger, J. P., Akiyama, T. E., & Meinke, P. T. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2005.03.003 · Cited by 713
NXY-059 for Acute Ischemic Stroke
Lees, K. R., Zivin, J. A., Ashwood, T., Davalos, A., Davis, S. M., Diener, H.-C., Grotta, J., Lyden, P., Shuaib, A., Hårdemark, H.-G., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052980 · Cited by 660
Moreno, S., Farioli-Vecchioli, S., & Cerù, M. P. (2004) · Neuroscience · doi:10.1016/j.neuroscience.2003.08.064 · Cited by 587
Heneka, M. T., Sastre, M., Dumitrescu-Ozimek, L., Hanke, A., Dewachter, I., Kuiperi, C., O'Banion, K., Klockgether, T., Van Leuven, F., & Landreth, G. E. (2005) · Brain · doi:10.1093/brain/awh452 · Cited by 565
Combs, C. K., Johnson, D. E., Karlo, J. C., Cannady, S. B., & Landreth, G. E. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-02-00558.2000 · Cited by 483
Neuroprotection for ischemic stroke: Two decades of success and failure
Cheng, Y. D., Al-Khoury, L., & Zivin, J. A. (2004) · NeuroRX · doi:10.1602/neurorx.1.1.36 · Cited by 384
Dehmer, T., Heneka, M. T., Sastre, M., Dichgans, J., & Schulz, J. B. (2004) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.02210.x · Cited by 382
Peroxisome proliferator-activated receptors and inflammation
Moraes, L. A., Piqueras, L., & Bishop-Bailey, D. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.08.007 · Cited by 376
Breidert, T., Callebert, J., Heneka, M. T., Landreth, G., Launay, J. M., & Hirsch, E. C. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.00990.x · Cited by 373
Peroxisome proliferator‐activated receptors in the cardiovascular system
Bishop‐Bailey, D. (2000) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703149 · Cited by 363
Blanquart, C., Barbier, O., Fruchart, J. C., Staels, B., & Glineur, C. (2003) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(03)00214-0 · Cited by 312
Self-citationCollino, M., Aragno, M., Mastrocola, R., Gallicchio, M., Rosa, A. C., Dianzani, C., Danni, O., Thiemermann, C., & Fantozzi, R. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2005.11.049 · Cited by 302
Feinstein, D. L., Galea, E., Gavrilyuk, V., Brosnan, C. F., Whitacre, C. C., Dumitrescu‐Ozimek, L., Landreth, G. E., Pershadsingh, H. A., Weinberg, G., & Heneka, M. T. (2002) · Annals of Neurology · doi:10.1002/ana.10206 · Cited by 294
Diverse compounds mimic Alzheimer disease–causing mutations by augmenting Aβ42 production
Kukar, T., Murphy, M. P., Eriksen, J. L., Sagi, S. A., Weggen, S., Smith, T. E., Ladd, T., Khan, M. A., Kache, R., Beard, J., et al. (2005) · Nature Medicine · doi:10.1038/nm1235 · Cited by 284
Sundararajan, S., Gamboa, J. L., Victor, N. A., Wanderi, E. W., Lust, W. D., & Landreth, G. E. (2005) · Neuroscience · doi:10.1016/j.neuroscience.2004.10.021 · Cited by 266
Cullingford, T. E., Bhakoo, K., Peuchen, S., Dolphin, C. T., Patel, R., & Clark, J. B. (1998) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1998.70041366.x · Cited by 234
Inoue, H., Jiang, X.-F., Katayama, T., Osada, S., Umesono, K., & Namura, S. (2003) · Neuroscience Letters · doi:10.1016/j.neulet.2003.09.001 · Cited by 232
Deplanque, D., Gelé, P., Pétrault, O., Six, I., Furman, C., Bouly, M., Nion, S., Dupuis, B., Leys, D., Fruchart, J.-C., et al. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-15-06264.2003 · Cited by 219
Self-citationShimazu, T., Inoue, I., Araki, N., Asano, Y., Sawada, M., Furuya, D., Nagoya, H., & Greenberg, J. H. (2005) · Stroke · doi:10.1161/01.str.0000152271.21943.a2 · Cited by 218
Peroxisome Proliferator-Activated Receptor α Agonists as Therapy for Autoimmune Disease
Lovett-Racke, A. E., Hussain, R. Z., Northrop, S., Choy, J., Rocchini, A., Matthes, L., Chavis, J. A., Diab, A., Drew, P. D., & Racke, M. K. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.9.5790 · Cited by 207
Zhao, Y., Patzer, A., Herdegen, T., Gohlke, P., & Culman, J. (2006) · The FASEB Journal · doi:10.1096/fj.05-5007com · Cited by 188
Peroxisome Proliferator-Activated Receptor γ Induces a Clearance Mechanism for the Amyloid-β Peptide
Camacho, I. E., Serneels, L., Spittaels, K., Merchiers, P., Dominguez, D., & De Strooper, B. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.3987-04.2004 · Cited by 168
Wada, K., Nakajima, A., Katayama, K., Kudo, C., Shibuya, A., Kubota, N., Terauchi, Y., Tachibana, M., Miyoshi, H., Kamisaki, Y., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m513786200 · Cited by 164
Collino, M., Aragno, M., Mastrocola, R., Benetti, E., Gallicchio, M., Dianzani, C., Danni, O., Thiemermann, C., & Fantozzi, R. (2006) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2006.04.030 · Cited by 163
Zambon, A., Gervois, P., Pauletto, P., Fruchart, J.-C., & Staels, B. (2006) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000204327.96431.9a · Cited by 162
Self-citationKielian, T., & Drew, P. D. (2002) · Journal of Neuroscience Research · doi:10.1002/jnr.10501 · Cited by 143
Kim, E. J., Kwon, K. J., Park, J.-Y., Lee, S., Moon, C., & Baik, E. J. (2002) · Brain Research · doi:10.1016/s0006-8993(02)02480-0 · Cited by 137
15d-Prostaglandin J 2 Protects Brain From Ischemia-Reperfusion Injury
Lin, T., Cheung, W.-M., Wu, J., Chen, J.-J., Lin, H., Chen, J.-J., Liou, J., Shyue, S., & Wu, K. K. (2005) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000201933.53964.5b · Cited by 127
Feinstein, D. L. (2003) · Diabetes Technology & Therapeutics · doi:10.1089/152091503763816481 · Cited by 116
Zhao, Y., Patzer, A., Gohlke, P., Herdegen, T., & Čulman, J. (2005) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2005.04200.x · Cited by 106
Combs, C. K., Bates, P., Karlo, J. C., & Landreth, G. E. (2001) · Neurochemistry International · doi:10.1016/s0197-0186(01)00052-3 · Cited by 101
Luquet, S. H., López‐Soriano, J., Holst, D., Gaudel, C., Jehl-Piétri, C., Fredenrich, A., & Grimaldi, P. A. (2004) · Biochimie · doi:10.1016/j.biochi.2004.09.024 · Cited by 98
Besson, V. C., Chen, X. R., Plotkine, M., & Marchand‐Leroux, C. (2005) · Neuroscience Letters · doi:10.1016/j.neulet.2005.06.019 · Cited by 98
Zhao, X., Ou, Z., Grotta, J. C., Waxham, M. N., & Aronowski, J. A. (2006) · Brain Research · doi:10.1016/j.brainres.2005.12.061 · Cited by 91
Hu, X., Nesic‐Taylor, O., Qiu, J., Rea, H. C., Fabian, R. H., Rassin, D. K., & Perez-Polo, J. R. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02968.x · Cited by 82
The Nonthiazolidinedione PPARγ Agonist L-796,449 Is Neuroprotective in Experimental Stroke
Pereira, M. P., Hurtado, O., Cárdenas, A., Alonso‐Escolano, D., Boscá, L., Vivancos, J., Nombela, F., Leza, J. C., Lorenzo, P. L., Lizasoaín, I., et al. (2005) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/01.jnen.0000178852.83680.3c · Cited by 76
Uryu, S., Harada, J., HISAMOTO, M., & Oda, T. (2002) · Brain Research · doi:10.1016/s0006-8993(01)03242-5 · Cited by 74
Neuroprotection for Ischaemic Stroke: An Unattainable Goal?
Liebeskind, D. S., & Kasner, S. E. (2001) · CNS Drugs · doi:10.2165/00023210-200115030-00001 · Cited by 55
Genovese, T., Mazzon, E., Paola, R. D., Cannavò, G., Muià, C., Bramanti, P., & Cuzzocrea, S. (2005) · Experimental Neurology · doi:10.1016/j.expneurol.2005.03.003 · Cited by 53
Tanaka, T., Fukunaga, Y., Itoh, H., Doi, K., Yamashita, J. K., Chun, T., Inoue, M., Masatsugu, K., Saito, T., Sawada, N., et al. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.10.056 · Cited by 44
PPAR agonists as direct modulators of the vessel wall in cardiovascular disease
Buchan, K. W., & Hassall, D. G. (2000) · Medicinal Research Reviews · doi:10.1002/1098-1128(200009)20:5<350::aid-med2>3.0.co;2-d · Cited by 39
Bernardo, A., Gasparini, L., Ongini, E., & Minghetti, L. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.09.012 · Cited by 19
Cited by
The neuroprotective properties of calorie restriction, the ketogenic diet, and ketone bodies
Maalouf, M., Rho, J. M., & Mattson, M. P. (2009) · Brain Research Reviews · doi:10.1016/j.brainresrev.2008.09.002 · Cited by 574
Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists
Kapadia, R. (2008) · Frontiers in Bioscience · doi:10.2741/2802 · Cited by 433
Sharma, P., Srivastava, P., Seth, A., Tripathi, P. N., Banerjee, A. G., & Shrivastava, S. K. (2019) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2018.12.006 · Cited by 331
Protective effects and mechanisms of sirtuins in the nervous system
Zhang, F., Wang, S., Gan, L., Vosler, P. S., Gao, Y., Zigmond, M. J., & Chen, J. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.09.001 · Cited by 211
Wan Ibrahim, W. N., Tofighi, R., Onishchenko, N., Rebellato, P., Bose, R., Uhlén, P., & Ceccatelli, S. (2013) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2013.03.003 · Cited by 65
Metadata
- Authors
- Bordet, R., Ouk, T., Petrault, O., Gelé, P., Gautier, S., Laprais, M., Deplanque, D., Duriez, P., Staels, B., Fruchart, J. C., & Bastide, M.
- Venue
- Biochemical Society Transactions
- Publisher
- Portland Press Ltd.
- Published
- 2006-10-25
- Volume
- 34
- Issue
- 6
- Pages
- 1341-1346
- ISSN
- 0300-5127 (ISSN-L)
- 1470-8752
- OpenAlex
- W2085973940
- Cited by
- 273
- References
- 43
- FWCI
- 6.14
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.